AFT Pharmaceuticals. - Postcard From the UK
Over the past twelve months, AFT Pharmaceuticals (AFT) has launched its Maxigesic tablet into the UK (branded as Combogesic).
292 Views
AFT Pharmaceuticals - Continued execution of footprint expansion
AFT Pharmaceuticals continues to make inroads in expanding its strategic market footprint. Most recently, it announced the entry into China with...
319 Views
AFT Pharmaceuticals - FY24 Result — Roaring Revenue
We retain our OUTPERFORM rating with an unchanged target price of NZ$4.60 (roll forward and peers re-rate offsets earnings downgrades).
366 Views
AFT Pharmaceuticals - Growth underpinned by international momentum
AFT Pharmaceuticals’ FY24 results demonstrated record earnings and sales, with 24.8% year-on-year sales growth. Revenues of NZ$195.4m were driven...
359 Views
AFT Pharmaceuticals - Maxigesic IV’s Brazil entry, a foray into LATAM
AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South...
304 Views